DOCSLIB.ORG

Hidden Severe Asthma in Primary Care Versus ISAR Cohort

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hidden Severe Asthma in Primary Care Versus ISAR Cohort Final report V1.5 16 th January 2020 1 Observational and Pragmatic Research Institute Pte Ltd Final report Hidden Severe Asthma in Primary Care versus ISAR Cohort Describe the extent of hidden (not referred) patients with severe asthma in a primary care setting versus ISAR and compare their demographic and clinical characteristics Date: 16th January 2020 AZ contact: Marianna Alacqua & Trung N. Tran OPRI Pte Ltd 5 Coles Lane Phone +44 (0) 1223 967884 Blk 883 North Bridge Road, Oakington #02-05 Southbank Cambridge CB24 3BA Web site http://www.opri.sg Singapore 198783 United Kingdom 1 Final report V1.5 16 th January 2020 2 Chief Investigator: Professor David Price, Professor of Primary Care Respiratory Medicine and Director of Observational and Pragmatic Research Institute Pte Ltd Office number: +44 2081233923 Skype ID: respiratoryresearch Email: [email protected] Research Lead: Dr Heath Heatley Observational and Pragmatic Research Institute Pte Ltd 5 Coles Lane, Oakington, Cambridgeshire CB24 3BA, United Kingdom Email: [email protected] Study sponsor: AstraZeneca Primary contacts Marianna Alacqua & Trung N. Tran Email: [email protected] & [email protected] 2 Final report V1.5 16 th January 2020 3 Title Hidden Severe Asthma in Primary Care vs. ISAR Cohort Subtitle Describe the extent of hidden (not referred) patients with severe asthma in a primary care setting versus ISAR and compare their demographic and clinical characteristics Final report version 1.5 EU PAS Registration Number EUPAS28611 ADEPT Approval Number ADEPT0319 Country of study United Kingdom Author OPRI Pte Ltd Blk 883 North Bridge Road #02-05 Southbank Singapore 198783 3 Final report V1.5 16 th January 2020 4 Contents 1.0 BACKGROUND ................................................................................................................................................ 7 2.0 STUDY AIMS AND OBJECTIVES ..................................................................................................................... 10 2.1 AIMS ......................................................................................................................................................................... 10 2.2 OBJECTIVES ................................................................................................................................................................ 10 3.0 STUDY DESIGN ............................................................................................................................................. 11 4.0 STUDY POPULATIONS AND DATA SOURCES ................................................................................................. 13 4.1 OPTIMUM PATIENT CARE RESEARCH DATABASE ................................................................................................................ 13 4.2 INTERNATIONAL SEVERE ASTHMA REGISTRY ...................................................................................................................... 14 5.0 STUDY OUTCOMES ....................................................................................................................................... 15 5.1 STUDY GROUPS ........................................................................................................................................................... 15 5.1 STUDY OUTCOMES ....................................................................................................................................................... 15 5.2 STATISTICAL ANALYSIS ................................................................................................................................................... 20 6.0 RESULTS ....................................................................................................................................................... 21 6.1 ELIGIBLE PATIENTS ....................................................................................................................................................... 21 6.2 CATEGORISATION BY GINA (2018) TREATMENT , EXACERBATIONS AND BY REFERRAL ................................................................ 21 6.3 CATEGORISATION ACCORDING TO MAINTENANCE AND ACUTE OCS USE .................................................................................. 24 6.4 DEMOGRAPHICS BY PATIENT GROUPS ............................................................................................................................... 25 6.5 CLINICAL CHARACTERISTICS BY PATIENT GROUPS ................................................................................................................. 30 6.6 COMORBIDITY CHARACTERISTICS BY PATIENT GROUPS ......................................................................................................... 42 6.7 ADDITIONAL FOLLOW -UP ANALYSIS ................................................................................................................................. 44 7.0 SUMMARY ................................................................................................................................................... 47 8.0 APPENDIX .................................................................................................................................................... 49 8.1 ALGORITHM TO SEPARATE ACUTE AND MAINTENANCE OCS USE ............................................................................................ 49 8.2 CODE LISTS ................................................................................................................................................................. 50 9.0 RESEARCH TEAM ........................................................................................................................................ 120 10.0 REFERENCES ............................................................................................................................................... 121 4 Final report V1.5 16 th January 2020 5 Index of Figures Figure 1 - Study Design ................................................................................................................ 12 Figure 2 - Number of patients by GINA (2018) treatment step....................................................... 22 Figure 3 - Proportion of patients in primary care with (a) high maintenance therapy asthma and potential severe asthma and (b) proportion of those with potential severe asthma who were not managed in specialist care, i.e. “hidden patients”. ............................................................ 23 Figure 4 - Categorisation of patients as either probable maintenance or acute OCS users ........... 24 Figure 5 - Patient Group: Age ....................................................................................................... 26 Figure 6 - Patient Group: Gender .................................................................................................. 26 Figure 7 - Patient Group: Ethnicity ................................................................................................ 27 Figure 8 - Patient Group: Height ................................................................................................... 27 Figure 9 - Patient Group: BMI ....................................................................................................... 28 Figure 10 - Patient Group: Smoking Status ................................................................................... 28 Figure 11 - Patient Group: Exacerbations ..................................................................................... 34 Figure 12 – Patient Group: Exacerbation Count Per Year ............................................................. 34 Figure 13 – Patient Group: Asthma Control .................................................................................. 34 Figure 14 – Patient Group: Blood Eosinophil Count ...................................................................... 34 Figure 15 – Patient Group: BEC Histogram................................................................................... 35 Figure 16 - Patient Group: FEV 1.................................................................................................... 36 Figure 17 – Patient Group: % Predicted FEV 1 ............................................................................... 36 Figure 18 – Patient Group: FVC .................................................................................................... 36 Figure 19 – Patient Group: % Predicted FVC ................................................................................ 36 Figure 20 – Patient Group: FEV 1/FVC ratio ................................................................................... 37 Figure 21 – Patient Group: Peak Expiratory Flow.......................................................................... 37 Figure 22 – Patient Group: Adherence .......................................................................................... 37 Figure 23 – Patient Group: ICS combination medication ............................................................... 37 Figure 24 – Patient Group: SABA, Theophylline and Biologic Medication ..................................... 38 Figure 25 – Patient Group: Comorbidities ..................................................................................... 43 Figure 26 – The number of patients with potentially severe asthma with referral records at any time .............................................................................................................................................
Load more

Recommended publications
  • Nasal Polyposis, Eosinophil Dominated Inflammation, and Allergy
    Thorax 2000;55 (Suppl 2):S79–S83 S79 Nasal polyposis, eosinophil dominated Thorax: first published as 10.1136/thorax.55.suppl_2.S79 on 1 October 2000. Downloaded from inflammation, and allergy Niels Mygind, Ronald Dahl, Claus Bachert A polyp is an oedematous mucous membrane computed tomographic (CT) scanning). The which forms a pedunculating process with a overall prevalence rate is probably about slim or broad stalk or base. Nasal polyps origi- 2–4%5–7 which increases with age of the study nate in the upper part of the nose around the population. Nasal polyposis occurs with a high openings to the ethmoidal sinuses. The polyps frequency in groups of patients with specified extend into the nasal cavity from the middle airway diseases (table 1). meatus, resulting in nasal blockage and re- Although symptomatic nasal polyposis is stricted airflow to the olfactory region. The rare in the general population, much higher polyp stroma is highly oedematous with a vary- figures for the occurrence of isolated nasal ing density of inflammatory cells. Nasal polyps have been obtained from necropsy polyposis, consisting of recurrent, multiple studies. A thorough endoscopic examination of polyps, is part of an inflammatory reaction removed nasoethmoidal blocks and endoscopic involving the mucous membrane of the nose, examination of unselected necropsy specimens paranasal sinuses, and often the lower airways. have shown polyps in as many as 25–40% of The polyps are easily accessible for immuno- specimens.89 logical and histological studies and an increas- Allergic rhinitis has a high prevalence rate of ing number of publications have appeared in about 15–20%.10 Most cases in the western recent years, including two monographs.12 world are caused by pollen allergy, having a Nasal polyps have long been associated with seasonal occurrence.
    [Show full text]
  • Non-Controlled Bronchial Asthma: the Contemporary Condition of the Problem
    1 UDC 616.248.1–085–084.001.5 Y.I. Feshchenko, I.F. Illyinskaya, L.V. Arefieva, L.M. Kuryk SO «National Institute Phthysiology and pulmonology named after F. G. Yanovsky NAMS of Ukraine» Non-controlled bronchial asthma: the contemporary condition of the problem Key words: bronchial asthma. Among all allergic diseases the most common is bron- of asthma [10, 13]. Different authors, when allocat- chial asthma (BA). In the world there are already about ing certain of its phenotypes and subtypes, rely on clini- 300 million patients with this ailment and in the forecast cal and morphological characteristics, the most significant by 2025 their number will increase by another 100 mil- triggers, the presence of concomitant pathology, as well lion. Chronization and deepening of the pathological pro- as unique responses to treatment. Thus, in the materials cess in asthma leads to a significant deterioration in the of GINA [10, 13, 20], there are those phenotypes of asthma quality of life of patients, decrease their activity, and also that can be easily identified. Distinguish: allergic asthma, causes growth disability and mortality from this illness. non-allergic asthma, childhood asthma / recurrent obstruc- According to official statistics in Ukraine, almost 500 pa- tive bronchitis, late-on asthma, asthma with obstruction tients with asthma suffer from 100 thousand adults, and this and a fixed rate of airflow, obesity asthma, occupational disease is diagnosed annually for about 8 thousand peo- asthma, asthma, severe asthma, and BA-COPD over- ple. According to experts, this does not correspond to the lapped syndrome. At the same time, the European respi- actual situation due to existing shortcomings in the diag- ratory community and the American Thoracic Community nosis of this pathology, but in fact the number of patients tend to focus more on a combination of clinical and patho- is much higher [15].
    [Show full text]
  • Nasal Polyposis: a Review
    Global Journal of Otolaryngology ISSN 2474-7556 Review Article Glob J Otolaryngol - Volume 8 Issue 2 May 2017 Copyright © All rights are reserved by Sushna Maharjan DOI: 10.19080/GJO.2017.0 Nasal Polyposis: A Review Sushna Maharjan1*, Puja Neopane2, Mamata Tiwari1 and Ramesh Parajuli3 1Department of Pathology, Chitwan Medical College Teaching Hospital, Nepal 2Department of Oral Medicine and Pathology, Health Sciences University of Hokkaido, Japan 3Department of Department of Otorhinolaryngology, Chitwan Medical College Teaching Hospital, Nepal Submission: May 07, 2017; Published: May 30, 2017 *Corresponding author: Sushna Maharjan, Department of Pathology, Chitwan Medical College Teaching Hospital (CMC-TH), P.O. Box 42, Bharatpur, Chitwan, Nepal, Email: Abstract Nasal polyp is a benign lesion that arises from the mucosa of the nasal sinuses or from the mucosa of the nasal cavity as a macroscopic usuallyedematous present mass. with The nasalexact obstruction,etiology is still rhinorrhea unknown and and postnasalcontroversial, drip. but Magnetic it is assumed resonance that imagingmain causes is suggested, are inflammatory particularly conditions to rule andout allergy. It is more common in allergic patients with asthma. Interleukin-5 has found to be significantly raised in nasal polyps. The patients seriousKeywords: conditions Allergy; such Interleukin-5; as neoplasia. Nasal Histopathological polyp; Neoplasia examination is also suggested to rule out malignancy and for definite diagnosis. Abbreviations: M:F- Male: Female; IgE: Immunoglobulin E; IL: Interleukin; CRS: Chronic Rhinosinusitis; HLA: Human Leucocyte Antigen; CT: Computerized Tomography; MRI: Magnetic Resonance Imaging Introduction the nose and nasal sinuses characterized by stromal edema and Nasal polyps are characterized by benign lesions that arise from the mucosa of the nasal sinuses, most often from the cause may be different.
    [Show full text]
  • Simplifying Asthma Management in Primary Care EDUCATIONAL SERIES RECOMMENDATIONS from the 2020 NZ ASTHMA GUIDELINES
    Simplifying asthma management A RESEARCH REVIEW™ in primary care EDUCATIONAL SERIES RECOMMENDATIONS FROM THE 2020 NZ ASTHMA GUIDELINES Making Education Easy 2021 About the expert This review is intended as an educational resource for primary healthcare professionals. It discusses the new Asthma and Respiratory Foundation NZ Adolescent and Adult Asthma Guidelines, published in the NZ Medical Professor Journal in June 2020, and how these may be implemented in primary care. The guidelines, which have Richard Beasley been developed by a multidisciplinary group of respiratory health experts, were last updated in 2016. Since CNZM, DSc(Otago), DM(Southampton), that time there have been significant advances in the understanding of how to best manage patients with MBChB, FRCP(London), FRACP, FAAAAI, FFOM(Hon), FAPSR(New Zealand), FERS, asthma. Taking into account the latest findings and incorporating recommendations from the Global Initiative FThorSoc, FRSNZ. for Asthma (GINA) Update strategy, the new guidelines provide simple, practical and evidenced-based recommendations for the diagnosis, assessment and management of asthma. Healthcare professionals may Richard Beasley is a physician at Wellington need to review the management of their asthma patients in light of the new guidelines. Regional Hospital, Director of the Medical Research Institute of New Zealand, and The 2020 Asthma and Respiratory Foundation NZ Adolescent and Adult Asthma Guidelines and a number of Professor of Medicine at Victoria University key clinical resources discussed in this review can be downloaded here. of Wellington. He is an Adjunct Professor at the University of Otago and Visiting Professor, University of Southampton, United Kingdom. Asthma: A major public health issue He is the Chair of the Asthma and Respiratory Foundation of New Zealand Adolescent and The prevalence of asthma in NZ is amongst the highest in the world, with up to 20% of children and adults affected Adult Asthma Guidelines.
    [Show full text]
  • Redalyc.Significance of Specific Igg Against Sensitizing Antigens In
    Revista Portuguesa de Pneumología ISSN: 0873-2159 [email protected] Sociedade Portuguesa de Pneumologia Portugal Sterclova, M.; Vasakova, M.; Metlicka, M. Significance of specific IgG against sensitizing antigens in extrinsic allergic alveolitis: Serological methods in EAA Revista Portuguesa de Pneumología, vol. 17, núm. 6, noviembre-diciembre, 2011, pp. 253-259 Sociedade Portuguesa de Pneumologia Lisboa, Portugal Available in: http://www.redalyc.org/articulo.oa?id=169722769004 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Documento descarregado de http://www.elsevier.pt el 21/05/2012. Cópia para uso pessoal, está totalmente proibida a transmissão deste documento por qualquer meio ou forma. Rev Port Pneumol. 2011;17(6):253---259 www.revportpneumol.org ORIGINAL ARTICLE Significance of specific IgG against sensitizing antigens in extrinsic allergic alveolitis: Serological methods in EAA M. Sterclova a,∗, M. Vasakova b, M. Metlicka b a Department of Respiratory Diseases, Thomayer’s University Hospital, Videnska, Prague, Czech Republic b Department of Immunology, Thomayer’s University Hospital, Videnska, Prague, Czech Republic Received 23 December 2010; accepted 20 June 2011 Available online 16 September 2011 KEYWORDS Abstract The aim of our study is to find differences in IgG in sera of potentially exposed and Aeroallergen; nonexposed individuals and to detect differences in concentrations of specific serum IgG among Hypersensitivity subjects with and without EAA. pneumonitis; Seventy-two patients being followed for suspected interstitial lung disease were included.
    [Show full text]
  • Global Strategy for Asthma Management and Prevention
    ® GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION REVISED 2006 Copyright © 2006 MCR VISION, Inc. All Rights Reserved Global Strategy for Asthma Management and Prevention The GINA reports are available on www.ginasthma.org. Global Strategy for Asthma Management and Prevention 2006 GINA EXECUTIVE COMMITTEE* Soren Erik Pedersen, MD Ladislav Chovan, MD, PhD Kolding Hospital President, Slovak Pneumological and Paul O'Byrne, MD, Chair Kolding, Denmark Phthisiological Society McMaster University Bratislava, Slovak Republic Hamilton, Ontario, Canada Emilio Pizzichini. MD Universidade Federal de Santa Catarina Motohiro Ebisawa, MD, PhD Eric D. Bateman, MD Florianópolis, SC, Brazil National Sagamihara Hospital/ University of Cape Town Clinical Research Center for Allergology Cape Town, South Africa. Sean D. Sullivan, PhD Kanagawa, Japan University of Washington Jean Bousquet, MD, PhD Seattle, Washington, USA Professor Amiran Gamkrelidze Montpellier University and INSERM Tbilisi, Georgia Montpellier, France Sally E. Wenzel, MD National Jewish Medical/Research Center Dr. Michiko Haida Tim Clark, MD Denver, Colorado, USA Hanzomon Hospital, National Heart and Lung Institute Chiyoda-ku, Tokyo, Japan London United Kingdom Heather J. Zar, MD University of Cape Town Dr. Carlos Adrian Jiménez Ken Ohta. MD, PhD Cape Town, South Africa San Luis Potosí, México Teikyo University School of Medicine Tokyo, Japan REVIEWERS Sow-Hsong Kuo, MD National Taiwan University Hospital Pierluigi Paggiaro, MD Louis P. Boulet, MD Taipei, Taiwan University of Pisa Hopital Laval Pisa, Italy Quebec, QC, Canada Eva Mantzouranis, MD University Hospital Soren Erik Pedersen, MD William W. Busse, MD Heraklion, Crete, Greece Kolding Hospital University of Wisconsin Kolding, Denmark Madison, Wisconsin USA Dr. Yousser Mohammad Tishreen University School of Medicine Manuel Soto-Quiroz, MD Neil Barnes, MD Lattakia, Syria Hospital Nacional de Niños The London Chest Hospital, Barts and the San José, Costa Rica London NHS Trust Hugo E.
    [Show full text]
  • Local Coverage Determination for Respiratory Therapy
    Local Coverage Determination (LCD): Respiratory Therapy (Respiratory Care) (L34430) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract Type Contract Number Jurisdiction State(s) Palmetto GBA A and B MAC 10111 - MAC A J - J Alabama Palmetto GBA A and B MAC 10211 - MAC A J - J Georgia Palmetto GBA A and B MAC 10311 - MAC A J - J Tennessee Palmetto GBA A and B and HHH MAC 11201 - MAC A J - M South Carolina Palmetto GBA A and B and HHH MAC 11301 - MAC A J - M Virginia Palmetto GBA A and B and HHH MAC 11401 - MAC A J - M West Virginia Palmetto GBA A and B and HHH MAC 11501 - MAC A J - M North Carolina Back to Top LCD Information Document Information LCD ID Original Effective Date L34430 For services performed on or after 10/01/2015 Original ICD-9 LCD ID Revision Effective Date L31593 For services performed on or after 01/29/2018 Revision Ending Date LCD Title N/A Respiratory Therapy (Respiratory Care) Retirement Date Proposed LCD in Comment Period N/A N/A Notice Period Start Date Source Proposed LCD 08/18/2016 N/A Notice Period End Date AMA CPT / ADA CDT / AHA NUBC Copyright Statement 10/02/2016 CPT only copyright 2002-2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use.
    [Show full text]
  • New Medical Treatments for Nasal Polyps
    New Medical Treatments for Nasal Polyps February 7, 2020 Brian Modena, MD, MSc 1 Disclosures Research support: NHLBI‐Supported Researcher Self Care Catalysts: architect of Health StorylinesTM app Personal Fees: AstraZeneca, GSK, Regeneron, Sanofi 42nd Annual Pulmonary and Allergy Update Objectives 1. Discuss the epidemiology, biology, pathophysiology, and symptoms of CRS with nasal polyposis (CRSwNP). 2. Review treatment guidelines and recommendations for CRSwNP. 3. Review the many scoring systems used to evaluate CRSwNP. 4. Discuss in detail the Phase II and Phase III clinical trials using biologics for treatment of CRSwNP. Nasal Polyposis Epidemiology Prevalence = ~4%1; (CRS = ~11‐12%)2 Costs: Genetic inheritance = ~14% 2 Increases with age; peak ~50 years CRS = ~$8 billion/year Caucasians = Th2‐driven inflammation. Per patient per year: $13,000; Male to female = 2:1 $26,000 if surgery performed. Asians = Th1‐driven inflammation. Association with allergic rhinitis is weak. Surgeries/year = ~500,000 Disease Prevalence estimates 1. Hastan, Fokkens, et al, 2011 Allergic rhinitis Adult: 0.1%; Children 1.5%1 2. Lange, Holst, et al., Clin Otolaryngol 2013. 3. Mygind. JACI. 1990 Dec;86(6 Pt 1):827‐9. Asthma 5‐22% 4. Schleimer RP. Annu Rev Pathol. 2017;12:331‐57. 5. Hunter TD, DeConde AS, Manes RP. J Med Econ. 2018;21(6):610‐5. CRS 20‐25%1‐4 6. Palmer JN, Messina JC, Biletch R, et al. Allergy Asthma Proc. 2018;39:1‐9. NSAID intolerance 36‐72% 7. Pearlman AN, Chandra RK, Chang D, et al. Am J Rhinol Allergy. 2009;23(2):145‐8. NSAID intolerance and asthma 80% 8.
    [Show full text]
  • Surgical Management of Polyps in the Treatment of Nasal Airway
    Surgical Management of Polyps in the TreatmentofNasal Airway Obstruction Samuel S. Becker, MD KEYWORDS FESS Nasal polyps Sinonasal polyps Polyp treatment Nasal obstruction In addition to their role in chronic rhinosinusitis and nasal congestion, sinonasal polyps are associated with significant nasal obstruction. Via a purely mechanical effect (ie, obstruction at its simplest level), polyps alter and otherwise block the normal flow of air through the nose. Similarly, by blocking the drainage pathways of the paranasal sinuses, sinus inflammation and its associated symptom of congestion occur. Because the pathway that leads to the formation of sinonasal polyps has not been completely elucidated, effective long-term treatments remain difficult to pinpoint. Management of these polyps, therefore, is a difficult challenge for the contemporary otolaryngologist. Some of the more common medical treatment options include: topical and oral steroids; macrolide antibiotics; diuretic nasal washes; and intrapolyp steroid injection. Surgical options include polypectomy and functional endoscopic sinus surgery (FESS). In addition, novel treatments for polyps are introduced with some frequency. This article presents an overview of management options for sino- nasal polyps, focusing on the indications, efficacy, and complications of the more common interventions. DIAGNOSIS AND PREVALENCE OF SINONASAL POLYPS Diagnosis of sinonasal polyps relies primarily on nasal endoscopy, with computed tomography (CT) to evaluate the extent of disease. Although unilateral
    [Show full text]
  • 1 Pathology Week 13: the Lung Ver.2
    Pathology week 13: the Lung ver.2 Atelectasis - either incomplete expansion of the lungs (neonatal) or collapse of previously inflated lung, producing areas of relatively airless pulmonary parenchyma - reduces oxygenation, predisposes to infection - reversible except if caused by contraction o acquired either: resorption atelectasis (obstruction airway, resorption trapped oxygen) • mucus plugging eg asthma, bronchitis, bronchiectasis, post op, FBs • mediastinum shifts towards affected lung compression atelectasis • effusion, pneumothorax, haemothorax, peritonitis – basal atelectasis • mediastinum shift away from affected lung contraction atelectasis • when local or general fibrotic changes in lung prevent full expansion Acute Lung Injury - a spectrum of pulmonary lesions (endothelial and epithelial) - initiated by many factors - susceptibility my be heritable - mediators include cytokines, oxidants, growth factors (incl TNF, IL1, IL6, IL10, TGFβ) - may manifest as congestion, oedema, surfactant disruption, atelectasis - may progress to ARDS or acute interstitial pneumonia Pulmonary Oedema - most common haemodynamic mechanism: ↑ hydrostatic pressure in LVF - heavy, wet lungs – initially basal due to greater hydrostatic pressure - alveolar capillaries engorged, intra-alveolar granular pink precipitate, alveolar microhaemorrhages and haemosiderin-laden macrophages (“heart failure” cells ) - longstanding LVF – many haemosiderin-laden macrophages, fibrosis, thickening alveolar walls – lungs firm and brown (brown induration) Oedema caused
    [Show full text]
  • Nebulizers: Diagnosis Codes – Medicare Advantage Policy Appendix
    UnitedHealthcare® Medicare Advantage Policy Appendix: Applicable Code List Nebulizers: Diagnosis Codes This list of codes applies to the Medicare Advantage Policy Guideline titled Approval Date: September 8, 2021 Nebulizers. Applicable Codes The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. The listing of a code does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply. Diagnosis Code Description For HCPCS Codes A7003, A7004, and E0570 A15.0 Tuberculosis of lung A22.1 Pulmonary anthrax A37.01 Whooping cough due to Bordetella pertussis with pneumonia A37.11 Whooping cough due to Bordetella parapertussis with pneumonia A37.81 Whooping cough due to other Bordetella species with pneumonia A37.91 Whooping cough, unspecified species with pneumonia A48.1 Legionnaires' disease B20 Human immunodeficiency virus [HIV] disease B25.0 Cytomegaloviral pneumonitis B44.0 Invasive pulmonary aspergillosis B59 Pneumocystosis B77.81 Ascariasis pneumonia E84.0 Cystic fibrosis with pulmonary manifestations J09.X1 Influenza due to identified novel influenza A virus with pneumonia J09.X2 Influenza due to identified novel influenza A virus with other
    [Show full text]
  • Statistical Analysis Plan
    Non-Interventional Study Protocol Study Code << DXXXRXXX >> Version V1.4 Date 14 July 2017 Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO) An observational study evaluating the benefits of early intervention with maintenance therapies to prevent or slow down rapid lung function decline in patients who are at high risk at the time of COPD diagnosis in the combined Optimum Patient Care Research Database and Clinical Practice Research Datalink databases TITLE PAGE Non-Interventional Study Protocol Study Code << DXXXRXXX >> Version 14 July 2017 Date 14 July 2017 TABLE OF CONTENTS PAGE TITLE PAGE ........................................................................................................... 1 TABLE OF CONTENTS ......................................................................................... 2 LIST OF ABBREVIATIONS .................................................................................. 5 RESPONSIBLE PARTIES ...................................................................................... 6 PROTOCOL SYNOPSIS DIAPLO STUDY ........................................................... 7 AMENDMENT HISTORY ................................................................................... 12 MILESTONES ....................................................................................................... 13 1. BACKGROUND AND RATIONALE .................................................................. 14 1.1 Background ...........................................................................................................
    [Show full text]